Vaccine breakthrough stops cancer returning in trial

A new jab extended the length of time patients were cancer free, but it is unclear for how long.

A new personalised vaccine could halve the risk of skin cancer returning in high-risk patients, a large trial has found.

The results mark a step forward in the effort to treat not just melanoma but other forms of cancer with vaccines designed to help keep patients disease-free.

Promising new cancer treatment is based on sequencing a tumour's DNA and making a patient's immune system attack their cancer cells

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine.  The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial o

More than 8,500 Americans are expected to die of melanoma this year

Landmark vaccine stops cancer returning in trial  The Times